韩国推出LEQEMBI, 这是一种新的阿尔茨海默氏治疗, 减缓疾病发展速度。 South Korea launches LEQEMBI, a new Alzheimer's treatment that slows disease progression.

韩国启动了LEQEMBI(Lecanemab),这是2024年5月批准的对早期阿尔茨海默氏病的新治疗。 South Korea has launched LEQEMBI (Lecanemab), a new treatment for early-stage Alzheimer's disease, approved in May 2024. Eisai和Biogen开发的这种药物是第一种通过针对脑中的氨基甲状腺细胞来减缓该疾病发展速度的药物。 Developed by Eisai and Biogen, it is the first drug to slow the progression of the disease by targeting amyloid-beta in the brain. 若干国家,包括美国、日本和中国,现在都可提供这种治疗。 The treatment is now available in several countries, including the U.S., Japan, and China. 韩国有超过900,000名痴呆病人, 其中约70%患老年痴呆症, 这种药物为管理这种疾病提供了新的希望。 With over 900,000 dementia patients in South Korea, about 70% of whom have Alzheimer's, this drug offers a new hope for managing the disease.